ClinicalTrials.gov
ClinicalTrials.gov Menu

AMPLATZER™ Amulet™ LAA Occluder Trial (Amulet IDE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02879448
Recruitment Status : Recruiting
First Posted : August 25, 2016
Last Update Posted : August 13, 2018
Sponsor:
Information provided by (Responsible Party):
St. Jude Medical

August 22, 2016
August 25, 2016
August 13, 2018
August 2016
February 2020   (Final data collection date for primary outcome measure)
  • Procedure-related complications, all-cause death, major bleeding [ Time Frame: 12-month ]
    The primary safety endpoint is a composite of procedure-related complications, or all-cause death, or major bleeding through 12 months
  • Ischemic stroke, systemic embolism [ Time Frame: 18-month ]
    The primary efficacy endpoint is a composite of ischemic stroke or systemic embolism through 18 months
  • Device closure [ Time Frame: 45-days ]
    The primary mechanism of action endpoint is device closure (defined as residual jet around the device ≤ 5 mm) at the 45-day visit documented by transesophageal echocardiogram (TEE/TOE) defined by Doppler flow
Same as current
Complete list of historical versions of study NCT02879448 on ClinicalTrials.gov Archive Site
  • All stroke, systemic embolism, or cardiovascular/unexplained death [ Time Frame: 18-month ]
    A composite of all stroke, systemic embolism, or cardiovascular/unexplained death at 18 months post-implant
  • Major bleeding post-device implant [ Time Frame: 18-month ]
    Major bleeding rate at 18 months post-implant: defined as Type 3 or greater based on the Bleeding Academic Research Consortium (BARC) definition
Same as current
Not Provided
Not Provided
 
AMPLATZER™ Amulet™ LAA Occluder Trial
AMPLATZER™ Amulet™ Left Atrial Appendage Occluder Randomized Controlled Trial
The Amulet™ device will be evaluated for safety and efficacy by demonstrating its performance is non-inferior to the commercially available WATCHMAN® left atrial appendage closure device in patients with non-valvular atrial fibrillation. Patients who are eligible for the trial will be randomized to receive either the Amulet device or the WATCHMAN device and will be followed for 5 years after device implant.
The Amulet IDE trial is a prospective, randomized, multi-center active control worldwide trial, designed to evaluate the safety and effectiveness of the AMPLATZER™ Amulet™ Left Atrial Appendage Occluder. Subjects will be randomized in a 1:1 ratio between the Amulet LAA occlusion device (treatment) or a Boston Scientific WATCHMAN® LAA closure device (Control). The trial will be conducted at up to 150 sites worldwide. All enrolled subjects will follow the protocol-required tests and assessments at each scheduled follow-up visit.
Interventional
Not Applicable
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Stroke
  • Device: Amulet Left Atrial Appendage Occluder
    Transcatheter left atrial appendage closure
  • Device: WATCHMAN Left Atrial Appendage Closure
    Transcatheter left atrial appendage closure
  • Experimental: Amulet
    Amulet left atrial appendage occluder
    Intervention: Device: Amulet Left Atrial Appendage Occluder
  • Active Comparator: WATCHMAN (Control)
    WATCHMAN left atrial appendage closure device
    Intervention: Device: WATCHMAN Left Atrial Appendage Closure
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
1878
1600
December 2023
February 2020   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  1. 18 years of age or older
  2. Documented paroxysmal, persistent, or permanent non-valvular atrial fibrillation (AF) and the patient has not been diagnosed with rheumatic mitral valvular heart disease
  3. At high risk of stroke or systemic embolism defined as CHADS2 score > 2 or a CHA2DS2-VASc score of ≥ 3
  4. Has an appropriate rationale to seek an alternative to warfarin or other anticoagulation medication
  5. Deemed by investigator to be suitable for short term warfarin therapy but deemed unable to take long term oral anticoagulation following the conclusion of shared decision making (see inclusion criteria #6)
  6. Deemed suitable for LAA closure by a multidisciplinary team of medical professionals (including an independent non-interventional physician) involved in the formal and shared decision- making process, and by use of an evidence-based decision tool on oral anticoagulation (final determination must be documented in the subject's medical record)
  7. Able to comply with the required medication regimen post-device implant
  8. Able to understand and willing to provide written informed consent to participate in the trial
  9. Able to and willing to return for required follow-up visits and examinations

Exclusion Criteria:

  1. Requires long-term oral anticoagulation therapy for a condition other than atrial fibrillation
  2. Contraindicated for or allergic to aspirin, clopidogrel, or warfarin use
  3. Indicated for chronic P2Y12 platelet therapy inhibitor
  4. Has undergone atrial septal defect (ASD) repair or has an ASD closure device implanted
  5. Has undergone patent foramen ovale (PFO) repair or has a PFO closure device implanted
  6. Implanted with a mechanical valve prosthesis
  7. Has any of the customary contraindications for a percutaneous catheterization procedure (e.g. subject is too small to accommodate the transesophageal echocardiogram (TEE/TOE) probe or required catheters, or subject has active infection or bleeding disorder)
  8. Stroke or transient ischemic attack (TIA) within 90 days prior to randomization or implant procedure (as applicable)
  9. Underwent any cardiac or non-cardiac intervention or surgery within 30 days prior to randomization, or intervention or surgery is planned within 60 days after implant procedure (cardioversion, ablation, cataract surgery, etc.)
  10. Myocardial infarction (MI) within 90 days prior to randomization
  11. New York Heart Association Class IV Congestive Heart Failure
  12. Left ventricular ejection Fraction (LVEF) <30%
  13. Symptomatic carotid artery disease (defined as >50% stenosis with symptoms of ipsilateral transient or visual TIA evidenced by amaurosis fugax, ipsilateral hemispheric TIAs or ipsilateral stroke); if subject has a history of carotid stent or endarterectomy the subject is eligible if there is <50% stenosis
  14. Reversible cause of AF (i.e. secondary thyroid disorders, acute alcohol intoxication, trauma, recent major surgical procedures)
  15. History of idiopathic or recurrent venous thromboembolism
  16. Left atrial appendage is obliterated or surgically ligated
  17. Resting heart rate >110 bpm
  18. Thrombocytopenia or anemia requiring transfusions
  19. Hypersensitivity to any portion of the device material or individual components of either the Amulet or Boston Scientific LAA closure device (e.g. nickel allergy)
  20. Actively enrolled or plans to enroll in a concurrent clinical study in which the active treatment arm may confound the results of this trial
  21. Subject is pregnant or pregnancy is planned during the course of the investigation
  22. Active endocarditis or other infection producing bacteremia
  23. Subject has had a transient case of AF (i.e. never previously detected, provoked/induced by surgical or catheter manipulations, etc.)
  24. Subjects with severe renal failure (estimated glomerular filtration rate <30ml/min/1.73m²
  25. Subject whose life expectancy is less than 2 years
  26. Presence of other anatomic or comorbid conditions, or other medical, social, or psychological conditions that, in the investigator's opinion, could limit the subject's ability to participate in the clinical trial or to comply with follow up requirements, or impact the scientific soundness of the clinical trial results.
Sexes Eligible for Study: All
18 Years and older   (Adult, Older Adult)
No
Contact: Maren Wagner 16517565585 maren.wagner@abbott.com
Contact: Brian Crowe 16517562783 brian.crowe@abbott.com
Australia,   Canada,   Denmark,   Germany,   Italy,   Netherlands,   Portugal,   Spain,   Switzerland,   United States
 
 
NCT02879448
SJM-CIP-10114
Yes
Not Provided
Plan to Share IPD: No
St. Jude Medical
St. Jude Medical
Not Provided
Study Chair: Dhanunjaya Lakkireddy, MD University of Kansas
Study Chair: David Thaler, MD, PhD The Comprehensive Stroke Center at Tufts Medical Center
Study Chair: Stephan Windecker, MD, PhD Inselspital, University of Bern
St. Jude Medical
August 2018

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP